Prognostic value of lymph-node dissection in patients undergoing radical cystectomy following previous oncological treatment for bladder cancer

References

• Skinner DG. Management of invasive bladder cancer: a meticulous pelvic node dissection can make a difference. J Urol 1982;128:34–6.
   PubMed Web of Science ®Google Scholar
• Dhar NB, Klein EA, Reuther AM, Thalmann GN, Madersbacher S, Studer UE. Outcome after radical cystectomy with limited or extended pelvic lymph node dissection. J Urol 2008;179:873–8.
   PubMed Web of Science ®Google Scholar
• Holmer M, Bendahl PO, Davidsson T, Gudjonsson S, Mansson W, Liedberg F. Extended lymph node dissection in patients with urothelial cell carcinoma of the bladder: can it make a difference? World J Urol 2009;27:521–6.
   PubMed Web of Science ®Google Scholar
• Herr HW. Extent of surgery and pathology evaluation has an impact on bladder cancer outcomes after radical cystectomy. Urology 2003;61:105–8.
   PubMed Web of Science ®Google Scholar
• Shelley MD, Barber J, Wilt T, Mason MD. Surgery versus radiotherapy for muscle invasive bladder cancer. Cochrane Database Syst Rev 2002;CD002079.
   PubMedGoogle Scholar
• Stenzl A, Cowan NC, De SM, Jakse G, Kuczyk MA, Merseburger AS, The updated EAU guidelines on muscle-invasive and metastatic bladder cancer. Eur Urol 2009;55:815–25.
   PubMed Web of Science ®Google Scholar
• Edsmyr F, Moberger G, Wadstrom L. Carcinoma of the bladder. Cystectomy after supervoltage therapy. Scand J Urol Nephrol 1971;5:215–21.
   PubMedGoogle Scholar
• Ramani VA, Maddineni SB, Grey BR, Clarke NW. Differential complication rates following radical cystectomy in the irradiated and nonirradiated pelvis. Eur Urol 2010;57:1058–63.
   PubMed Web of Science ®Google Scholar
• Nieuwenhuijzen JA, Horenblas S, Meinhardt W, van Tinteren H, Moonen LM. Salvage cystectomy after failure of interstitial radiotherapy and external beam radiotherapy for bladder cancer. BJU Int 2004;94:793–7.
   PubMed Web of Science ®Google Scholar
• Bochner BH, Figueroa AJ, Skinner EC, Lieskovsky G, Petrovich Z, Boyd SD, Salvage radical cystoprostatectomy and orthotopic urinary diversion following radiation failure. J Urol 1998;160:29–33.
   PubMed Web of Science ®Google Scholar
• Jensen JB, Ulhoi BP, Jensen KM. Lymph node mapping in patients with bladder cancer undergoing radical cystectomy and lymph node dissection to the level of the inferior mesenteric artery. BJU Int 2010;106:199–205.
   PubMed Web of Science ®Google Scholar
• Hautmann RE, Gschwend JE, de Petriconi RC, Kron M, Volkmer BG. Cystectomy for transitional cell carcinoma of the bladder: results of a surgery only series in the neobladder era. J Urol 2006;176:486–92.
   PubMed Web of Science ®Google Scholar
• Stein JP, Cai J, Groshen S, Skinner DG. Risk factors for patients with pelvic lymph node metastases following radical cystectomy with en bloc pelvic lymphadenectomy: concept of lymph node density. J Urol 2003;170:35–41.
   PubMed Web of Science ®Google Scholar
• Mills RD, Turner WH, Fleischmann A, Markwalder R, Thalmann GN, Studer UE. Pelvic lymph node metastases from bladder cancer: outcome in 83 patients after radical cystectomy and pelvic lymphadenectomy. J Urol 2001;166:19–23.
   PubMed Web of Science ®Google Scholar
• Steven K, Poulsen AL. Radical cystectomy and extended pelvic lymphadenectomy: survival of patients with lymph node metastasis above the bifurcation of the common iliac vessels treated with surgery only. J Urol 2007;178:1218–23.
   PubMed Web of Science ®Google Scholar
• Vieweg J, Gschwend JE, Herr HW, Fair WR. Pelvic lymph node dissection can be curative in patients with node positive bladder cancer. J Urol 1999;161:449–54.
   PubMed Web of Science ®Google Scholar
• Herr HW, Donat SM, Bajorin DF. Post-chemotherapy surgery in patients with unresectable or regionally metastatic bladder cancer. J Urol 2001;165:811–14.
   PubMed Web of Science ®Google Scholar
• Sweeney P, Millikan R, Donat M, Wood CG, Radtke AS, Pettaway CA, Is there a therapeutic role for post-chemotherapy retroperitoneal lymph node dissection in metastatic transitional cell carcinoma of the bladder? J Urol 2003;169:2113–17.
   PubMed Web of Science ®Google Scholar
• de Vries RR, Nieuwenhuijzen JA, Meinhardt W, Bais EM, Horenblas S. Long-term survival after combined modality treatment in metastatic bladder cancer patients presenting with supra-regional tumor positive lymph nodes only. Eur J Surg Oncol 2009;35:352–5.
   PubMed Web of Science ®Google Scholar
• Ghadjar P, Burkhard FC, Gautschi O, Thalmann GN, Studer UE. Induction chemotherapy for unresectable urothelial carcinoma of the bladder. BJU Int 2011;107:894–7.
   PubMed Web of Science ®Google Scholar
• Herr HW. Outcome of patients who refuse cystectomy after receiving neoadjuvant chemotherapy for muscle-invasive bladder cancer. Eur Urol 2008;54:126–32.
   PubMed Web of Science ®Google Scholar
• Advanced Bladder Cancer Meta-analysis Collaboration. Neoadjuvant chemotherapy for invasive bladder cancer. Cochrane Database Syst Rev 2005(2);CD005246.
   PubMed Web of Science ®Google Scholar
• Siefker-Radtke AO, Walsh GL, Pisters LL, Shen Y, Swanson DA, Logothetis CJ, Is there a role for surgery in the management of metastatic urothelial cancer? The M. D. Anderson experience. J Urol 2004;171:145–8.
   Google Scholar
• Black PC, Dinney CP, Brown GA, Kassouf W, Siefker-Radtke AO, Munsell MF, The role of radical cystectomy in patients with clinical T4b bladder cancer. Urol Oncol 2011; 29:157–61.
   PubMed Web of Science ®Google Scholar
• Fossa SD, Sternberg C, Scher HI, Theodore CH, Mead B, Dearnaley D, Survival of patients with advanced urothelial cancer treated with cisplatin-based chemotherapy. Br J Cancer 1996;74:1655–9.
   PubMed Web of Science ®Google Scholar
• Als AB, Sengelov L, von der Maase H. Long-term survival after gemcitabine and cisplatin in patients with locally advanced transitional cell carcinoma of the bladder: focus on supplementary treatment strategies. Eur Urol 2007;52:478–86.
   PubMed Web of Science ®Google Scholar
• Dodd PM, McCaffrey JA, Herr H, Mazumdar M, Bacik J, Higgins G, Outcome of postchemotherapy surgery after treatment with methotrexate, vinblastine, doxorubicin, and cisplatin in patients with unresectable or metastatic transitional cell carcinoma. J Clin Oncol 1999;17:2546–52.
   PubMed Web of Science ®Google Scholar